Nocturne Acquisition Corporation Announces Postponement of Extraordinary General Meeting

SANTA ANA, CA / ACCESSWIRE / February 5, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of a second postponement of the meeting date for the Extraordinary General Meeting that was to be held on January 30, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The Extraordinary General Meeting that was postponed until February 6, 2024 has been postponed further and will now be held virtually on February 27, 2024 at 9:00 a.m. Eastern Time. The Company plans to continue to solicit proxies from shareholders during the period prior to the Extraordinary General Meeting. The record date for the Extraordinary General Meeting remains the close of business on December 29, 2023. No changes have been made in the proposals to be voted on by the shareholders at the postponed meeting. Shareholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the record date may vote, even if they have subsequently sold their shares. The deadline by which shareholders must exercise their redemption rights in connection with the Extraordinary General Meeting has been extended to two business days prior to the second postponed meeting.

About Nocturne Acquisition Corp.

The Company is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. While the Company may pursue an acquisition opportunity in any industry or sector, the Company focuses its search for targets bringing to market disruptive technologies in the blockchain/crypto and artificial intelligence technology sectors. Equity value of potential targets is expected to be in the $300 million to $1 billion USD range.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions. . Such forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties. The Company does not undertake any obligation to update forward-looking statements as a result of new information, future events or developments or otherwise.

Additional Information and Where to Find It

A full description of the terms of that certain Agreement and Plan of Merger and Reorganization, dated December 30, 2022, by and among Nocturne, Cognos, and Nocturne Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Nocturne, in connection with the proposed Merger is provided in the definitive Registration Statement which includes a prospectus with respect to the combined company’s securities to be issued in connection with the Merger and a proxy statement with respect to the Extraordinary General Meeting to vote on the Merger. The definitive proxy statement/prospectus included in the Registration Statement has been mailed to stockholders of Nocturne as of the record date of December 29, 2023. Stockholders are also able to obtain a copy of the Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to Nocturne Acquisition Corporation, P.O Box 25739, Santa Ana, CA 92799, Attention Thomas Ao. The preliminary and definitive proxy statement/prospectus included in the Registration Statement can also be obtained, without charge, at the SEC’s website (

Participants in Solicitation

Nocturne, Cognos and their respective directors and officers may be deemed to be participants in the solicitation of proxies from Nocturne’s stockholders in connection with the proposed business combination. Information about Nocturne’s directors and executive officers and their ownership of Nocturne’s securities is set forth in Nocturne’s filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed business combination may be obtained by reading the Registration Statement.

MBTC Company/Media Contact:

MBTC Investor Relations Contact:

Chris Tyson/Doug Hobbs
MZ SPAC Investor Relations
(949) 491-8235

SOURCE: Nocturne Acquisition Corporation

View the original press release on

Labor Smart Inc., LTNC, Next Gen Beverages Launches New eSports Division

JACKSON, WY / ACCESSWIRE / February 5, 2024 / Labor Smart, Inc. (OTC PINK:LTNC) through its wholly-owned subsidiary, Next Gen Beverages, maker of performance drink brand LOCK’DIN, is pleased to announce the launch of its new eSports Gaming Division.

The division was developed to accommodate the rapidly growing number of eSports (electronic sports) athletes taking part in multiplayer video game competitions, particularly between amateur and professional players and teams. The rapidly growing phenomenon surrounding eSports continues to gather momentum as the intersection of gaming and sports offers an innovative wave of branding opportunities, engaging content, and activations for millions across the world. The total market value for the eSports industry is estimated at over 1.6 billion. We encourage every "gamer" to visit for more information and to sign up.

Quoting our Interim CEO, Tom Zarro, "I am pleased to see the gaming enthusiasts have a dedicated space to participate in their eSports competitions, enjoy our LOCK’DIN beverage products, grow their community, and do so in an environment where they’re most comfortable. It is my goal to see this division have its dedicated product line very soon, to be trademarked under another name, therefore delivering more to the parent company and the LTNC shareholder value proposition. We would love our current and potential shareholders, consumers, and gaming enthusiasts to please join our affiliate program and learn more about what’s to come. "

All current and future products feature innovative, science-based formulas, many with branded, trademarked ingredients from such respected providers as Nutrition 21 and Applied Food Sciences. One example is the LOCK’DIN Nootropic Performance Drink featuring a strategic combination of two ingredients, nooLVL® and AmaTea MAX®, which have been shown in research to improve aspects of gaming performance including memory, focus, reaction time, and information processing. These benefits not only unlock peak performance for gamers but for everyday individuals who desire improved brain performance as well.

Please direct inquiries regarding the LOCK’DIN gaming division to its dedicated director at

On Tuesday, February 6th, 2024, at 8pm EST, we encourage shareholders and customers of LOCK’DIN Beverages to please join us on @lockdinnews Twitter Spacesto learn more about the ongoing developments in the company and our product line.

We encourage shareholders to register their email addresses with LOCK’DIN Beverages to stay up to date with product news and receive exclusive shareholder-only promotions. Sign up at

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Labor Smart, Inc. ("Labor Smart" or the "Company"). Forward-looking statements are based on the expectations, estimates, or projections of the Company’s management as of the date of this press release. Although Labor Smart’s management believes these expectations, estimates, or projections to be reasonable as of the date of this presentation, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause the Company’s actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Labor Smart’s actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" sections in the Company’s filings with the Securities and Exchange Commission, which are available for viewing on the SEC’s EDGAR website. These forward-looking statements speak only as of the date of this press release and, except as required by law, Labor Smart specifically disclaims any obligation to update these forward-looking statements, even if new information becomes available in the future.

Tom Zarro, Interim CEO and Board Member
Mailing Address
P.O. Box 2922
Jackson, WY 83001-2922

SOURCE: Labor Smart, Inc.

View the original press release on

Physician Growth Partners Announces Promotion of Robert Aprill, From Managing Director to Partner

BOSTON, MA / ACCESSWIRE / February 5, 2024 / Physician Growth Partners ("PGP"), a leading sell-side healthcare investment banking and transaction advisory firm, is pleased to announce the promotion of Robert Aprill to the position of Partner effective February 1, 2024.

Since joining PGP in January 2021 as a Managing Director, Robert has been instrumental in growing PGP’s capabilities through his experience and knowledge of the healthcare ecosystem. He was keen on driving PGP’s continued growth year-over-year, empowering Physician Growth Partners to become the lead advisor in representing physician groups in transactions with private equity. Robert has led PGP’s efforts in orthopedics, urology, oral surgery, specialty dentistry, and behavioral health, among other specialties.

"Robert’s accelerated promotion to partner is a testament to his exceptional leadership and invaluable contributions. His mentorship, commitment, and role in driving PGP’s growth has made him a leader in this organization. As a partner, Robert will continue to steer us towards new heights, bringing his expertise and dedication to help further elevate our firm’s achievements in the healthcare investment banking sector," said Michael Kroin, CEO and Managing Partner.

"As an individual I have always placed the utmost importance on aligning myself with people who share common goals and values. PGP was founded on the premise of providing a white glove approach to client service, while creating a culture of respect, loyalty, and teamwork. I am excited and honored to join PGP as a Partner and to continue working every day, strengthening our position as the premier investment bank in the healthcare sector," said Mr Aprill.

About Physician Growth Partners

Physician Growth Partners is one of the most active sell-side healthcare investment banking firms in the US and is dedicated to representing specialty physician practices in transactions with private equity. PGP creates value by providing operational support, strategic positioning, and transaction execution from start to finish. Founded in 2018, PGP has advised more than 60 practices to successful private equity partnerships.

Watch episode 27 of "Fixing Healthcare…From The Trenches", where Robert Aprill joined Dr Alejandro Badia to discuss the dynamic and consolidating healthcare landscape

For more information about Physician Growth Partners, please visit or contact us at 432 N. Clark Street, Ste. 200, Chicago, IL 60654

SOURCE: Physician Growth Partners

View the original press release on

Vivakor Achieves Milestone for its RPC in Houston, Texas

Completed Factory Acceptance Test and Now Working Toward Commercial Operations

DALLAS, TX / ACCESSWIRE / February 5, 2024 / Vivakor, Inc. (Nasdaq:VIVK) ("Vivakor" or the "Company"), a clean energy technology company focused on the oil remediation and natural resources sectors, is pleased to announce the completion of the factory acceptance tests for its Remediation Processing Center (RPC) in Houston, Texas.

The tests were done in conjunction with RK Energy and checked out all the Control Logic, Operating Screens, PLC controls, Plant Interlocks and all plant equipment/instruments/devices.

This represents a major milestone in moving forward towards operation. The Vivakor team is pressing forward to gain the necessary permits and access to power for the site, which are the final steps needed to get the RPC into commercial operation.

Vivakor Chairman and Chief Executive Officer James Ballengee commented, "This is a significant milestone and provides support for some of the rationale behind our acquisitions from the summer of 2022, as we believed in the synergies between the RPCs and our oil and gas expertise. We have now successfully completed the onsite Factory Acceptance Tests (FAT) on our Remediation Processing Center (RPC) located in Houston, Texas, and look forward to moving this unit into commercial operation."

Ballengee, continued, "We are excited to establish this first-of-its-kind center for processing and recovery of tank bottom sludge and other oil-industry waste. Millions of tons of this waste are generated annually, just within the U.S. and are typically treated with hardening agents and disposed of in hazardous waste landfills. The goal of our facility is to process this waste and recover and recycle the embedded oil – reducing the need to drill for new oil and preventing the waste from ending up in landfills."

Vivakor previously entered into a 10-year Land Lease Agreement, under which the Company agreed to lease approximately 3.5 acres of land in Houston, Texas (commonly known as The San Jacinto River & Rail Park, 18511 Beaumont Highway, Houston, Texas). When the RPC’s main plant is fully operational, Vivakor’s expectation is for processing 700 to 900 tons of raw material a day for an average of 600 to 800 barrels of crude production on average and production of 100’s of tons of clean solids with less than 1% Hydrocarbons per 24-hour day.

As plant wide construction and main power to the facility finalizes along with the construction completion of the Wash Plant, the RPC will be ready to perform its final tuning using cleaning fluids and raw materials fed to it by the wash plant/raw material handling side.

Once operational, this will be Vivakor’s first site to process tank bottom sludge and other oil-industry based waste. The plan for the facility is to recover the oil within the sludge utilizing its patented, environmentally-friendly RPC processing technology, which has been validated for the treatment of soil. Recent testing of the RPC technology at another site showed the treated soil Total Petroleum Hyrdrocarbons range was measured between 0.2% to 0.4%, which was well within the excepted range of TPH < 1%.

RPCs are designed, engineered and manufactured off site and then moved on site for construction and the Factory Acceptance Test.

About Vivakor, Inc.

Vivakor, Inc. (NASDAQ:VIVK), is a clean energy technology company focused on the oil remediation and natural resources sectors. Vivakor’s corporate mission is to create, acquire, accumulate, and operate distinct assets, intellectual properties, and exceptional technologies. Its Silver Fuels Delhi, LLC, and White Claw Colorado City, LLC subsidiaries include crude oil gathering, storage, and transportation facilities, which feature long-term ten year take-or-pay contracts.

The Company’s patented Remediation Processing Centers allows for the environmentally-friendly recovery of bitumen (heavy crude) and other hydrocarbons from the remediation of contaminated soils. It is believed to be the only remediation system that can clean soils with more than 5% by weight oil contamination while recovering the oil and leaving the soil fully viable for reuse. Once operational, its Remediation Processing Centers will focus on extraction from shallow, oil-laden sands, along with generating petroleum-based remediation projects in Kuwait and in Houston, Texas.

For more information, please visit our website:

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the Securities and Exchange Commission, which factors may be incorporated herein by reference. Forward-looking statements may be identified but not limited by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Investors Contact:


SOURCE: Vivakor

View the original press release on

ARRALYZE(R) Launches CellShepherd(R): A Fully Autonomous Single-Cell Platform For Real-Time Monitoring Of Functional Assays

GARBSEN, GERMANY / ACCESSWIRE / February 5, 2024 / ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®. After a successful beta-testing phase in 2023, this groundbreaking platform is now ready to revolutionize cell-based research and development across biomedical and various life science fields.

CellShepherd®: Redefining Single-Cell Analysis
CellShepherd®, developed by ARRALYZE®, responds to the urgent need for advanced functional cell screening technologies in academic and industrial laboratories. It stands out with ARRALYZE’s proprietary nanowell glass arrays, which miniaturize cell-based assays while enabling real-time monitoring at the single-cell level. This autonomous platform boasts precise dispensing into nanoliter glass wells and supports (co)-culturing under climate-controlled, sterile conditions. Its capabilities extend to real-time imaging through a brightfield microscope and three fluorescent channels. Leveraging advanced AI-driven analysis, CellShepherd® accurately counts and tracks cells, offering vital insights into various parameters. This innovation promises a new era in scientific research characterized by precision, control, and deep insights.

Meeting Market Demands: The ARRALYZE® Vision
CellShepherd® is designed to fulfill the growing demand for technologies capable of studying small and large cell populations at the single-cell level and isolating target cells. By adopting a holistic approach, ARRALYZE® enables customers to uncover individual characteristics of heterogeneous cell populations and gain insight into the kinetics of experiments, monitoring functionality at different time points. This approach overcomes challenges such as harsh experiment conditions, limited microenvironment control, and difficulties maintaining cell viability.

Key Features and Benefits

  • Proprietary nanowell glass arrays for precise miniaturization of cell-based assays.
  • Precise dispensing of cell suspensions with outstanding viability.
  • Autonomous operation supporting (co)-culturing in a climate-controlled, sterile environment.
  • Advanced real-time imaging capabilities including a brightfield microscope and three fluorescent channels.
  • AI-driven analysis for accurate cell counting and tracking.
  • User-friendly interface designed for ease of experiment setup, monitoring, and analysis.
  • Ability to isolate live cells for downstream processes, enhancing versatility and application scope.

About LPKF
LPKF Laser & Electronics SE, the parent company of ARRALYZE, is a leading provider of laser-based solutions for the technology industry. Founded in 1976, the company is headquartered in Germany, and is active worldwide through subsidiaries and representatives. The establishment of ARRALYZE as a dedicated division signifies LPKF’s commitment to innovation and excellence in the biotechnological sector. LPKF Laser & Electronics SE shares are traded in the Prime Standard segment of Deutsche Börse (ISIN 0006450000).

For more information about CellShepherd® and ARRALYZE®, please visit or contact us by email at

ARRALYZE is part of LPKF group:
LPKF Laser & Electronics SE
Osteriede 7
D-30827 Garbsen
Fon: +49 (0) 5131 7095-0
Fax: +49 (0) 5131 7095-90

End of Media Release

SORUCE: LPKF Laser & Electronics SE

View the original press release on